0

Journal Articles

in Drug Therapy
 241-260 of 342 Articles
Editorial |  November 09, 2005
Appropriate Use of Antimicrobial Drugs:  A Better Prescription Is Needed
J. Todd Weber, MD
JAMA. 2005;294(18):2354-2356. doi:10.1001/jama.294.18.2354.
Medical News and Perspectives |  November 09, 2005
Biomedical Journals Probe Peer Review
JAMA. 2005;294(18):2287-2288. doi:10.1001/jama.294.18.2287.
Original Contribution |  November 09, 2005 FREE
Clinical Decision Support and Appropriateness of Antimicrobial Prescribing:  A Randomized Trial
Matthew H. Samore, MD; Kim Bateman, MD; Stephen C. Alder, PhD; et al.
JAMA. 2005;294(18):2305-2314. doi:10.1001/jama.294.18.2305.
Editorial |  September 07, 2005
Rainbow to Dark Clouds
Catherine D. DeAngelis, MD, MPH
JAMA. 2005;294(9):1107. doi:10.1001/jama.294.9.1107.
Original Contribution |  September 07, 2005 FREE
Medical Students’ Exposure to and Attitudes About Drug Company Interactions:  A National Survey
Frederick S. Sierles, MD; Amy C. Brodkey, MD; Lynn M. Cleary, MD; et al.
JAMA. 2005;294(9):1034-1042. doi:10.1001/jama.294.9.1034.
Capitol Health Call |  July 13, 2005
Accelerated Approval Abuse
JAMA. 2005;294(2):171. doi:10.1001/jama.294.2.171-b.
Original Contribution |  June 22, 2005 FREE
Information Leaflet and Antibiotic Prescribing Strategies for Acute Lower Respiratory Tract Infection:  A Randomized Controlled Trial
Paul Little, MD; Kate Rumsby, BA; Joanne Kelly, BSc; et al.
JAMA. 2005;293(24):3029-3035. doi:10.1001/jama.293.24.3029.
Capitol Health Call |  May 11, 2005
Drug Reimportation Talks
JAMA. 2005;293(18):2204. doi:10.1001/jama.293.18.2204-c.
Special Communication |  May 04, 2005
The Research on Adverse Drug Events and Reports (RADAR) Project
Charles L. Bennett, MD, PhD, MPP; Jonathan R. Nebeker, MS, MD; E. Allison Lyons, BA; et al.
JAMA. 2005;293(17):2131-2140. doi:10.1001/jama.293.17.2131.
Original Contribution |  April 27, 2005 FREE
Influence of Patients’ Requests for Direct-to-Consumer Advertised Antidepressants:  A Randomized Controlled Trial
Richard L. Kravitz, MD, MSPH; Ronald M. Epstein, MD; Mitchell D. Feldman, MD, MPhil; et al.
JAMA. 2005;293(16):1995-2002. doi:10.1001/jama.293.16.1995.
Capitol Health Call |  April 13, 2005
Clinical Trial Registry
JAMA. 2005;293(14):1718. doi:10.1001/jama.293.14.1718-c.
Medical News and Perspectives |  April 06, 2005
Pharmaceutical Industry Funding for Residencies Sparks Controversy
JAMA. 2005;293(13):1572-1580. doi:10.1001/jama.293.13.1572.
Capitol Health Call |  March 09, 2005
Drug Importation Debate
JAMA. 2005;293(10):1181. doi:10.1001/jama.293.10.1181-d.
Original Contribution |  March 09, 2005 FREE
Role of Computerized Physician Order Entry Systems in Facilitating Medication Errors
Ross Koppel, PhD; Joshua P. Metlay, MD, PhD; Abigail Cohen, PhD; et al.
JAMA. 2005;293(10):1197-1203. doi:10.1001/jama.293.10.1197.
From the Centers for Disease Control and Prevention |  March 02, 2005 FREE
Publication of
JAMA. 2005;293(9):1052-1056. doi:10.1001/jama.293.9.1056.
Commentary |  January 19, 2005
A Perspective on US Drug Reimportation
Niteesh K. Choudhry, MD, FRCPC; Allan S. Detsky, MD, PhD, FRCPC
JAMA. 2005;293(3):358-362. doi:10.1001/jama.293.3.358.
Commentary |  December 01, 2004
Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions:  A Counterpoint
Brian L. Strom, MD, MPH
JAMA. 2004;292(21):2643-2646. doi:10.1001/jama.292.21.2643.
Controversies |  December 01, 2004
Authors’ Reply to Bayer’s Response to “Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis”
Bruce M. Psaty, MD, PhD; Curt D. Furberg, MD, PhD; Wayne A. Ray, PhD; et al.
JAMA. 2004;292(21):2658-2659. doi:10.1001/jama.292.21.2658.
Controversies |  December 01, 2004
Bayer’s Response to “Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis”
Joseph D. Piorkowski, DO, JD, MPH
JAMA. 2004;292(21):2655-2657. doi:10.1001/jama.292.21.2655.
Editorial |  December 01, 2004
Postmarketing Surveillance—Lack of Vigilance, Lack of Trust
Phil B. Fontanarosa, MD; Drummond Rennie, MD; Catherine D. DeAngelis, MD, MPH
JAMA. 2004;292(21):2647-2650. doi:10.1001/jama.292.21.2647.

Sign In

Register for a FREE personal account

and access these and other features:

Register Now

Want to Subscribe?

Learn More about subscription options.

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

From The JAMA Network
JAMA Internal Medicine
Viewpoint  |  May 13, 2013
Adulterated Sexual Enhancement Supplements:  More Than Mojo
Pieter A. Cohen, MD; Bastiaan J. Venhuis, PhD
JAMA Internal Medicine
Original Investigation  |  February 4, 2013
Dietary and Supplemental Calcium Intake and Cardiovascular Disease Mortality:  The National Institutes of Health–AARP Diet and Health Study
Qian Xiao, PhD; Rachel A. Murphy, PhD; Denise K. Houston, PhD; et al.
JAMA Internal Medicine
Invited Commentary  |  February 4, 2013
Are Calcium Supplements Harmful to Cardiovascular Disease?:  Comment on “ Dietary and Supplemental Calcium Intake and Cardiovascular Diseases Mortality: The National Institutes of Health–AARP Diet and Health Study”
Susanna C. Larsson, PhD
JAMA Internal Medicine
Research Letters  |  April 22, 2013
Trends in On-label and Off-label Modafinil Use in a Nationally Representative Sample
Renée A. Peñaloza, MS; Urmimala Sarkar, MD, MPH; David M. Claman, MD; et al.
© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems